arrow
S

Sandra M. Swain

medstar health
H指数:87
被引数:5.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack

快速实现CYP2C19基因分型以指导缺血性卒中和短暂性脑缺血发作二级预防的抗血小板治疗

2026-10-020
PRE
Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events

基于性别的预后在行业赞助的晚期实体瘤试验中:一项关于生存期和不良事件的个体参与者数据荟萃分析

2026-04-010
PREAI
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies

根据剂量对曲妥珠单抗德鲁替康的安全性特征进行表征:一项跨越DESTINY研究的合并分析

2026-01-010
PRE
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者接受化疗和抗HER2治疗后卵巢功能丧失

2025-09-013
OAAI
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study
2024-09-300
OA
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

6th和7th晚期乳腺癌管理国际共识指南 (ABC指南6和7)

BREAST
IF7.9
2024-08-0122
OAAI
Tailoring neo/adjuvant systemic therapy in breast cancer: The advent of a personalized approach-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations

定制乳腺癌的新/辅助系统治疗: 个性化方法的出现-乳腺妇科和免疫肿瘤学国际癌症会议 (BGICC) 共识和建议

CANCER
IF5.1
2024-07-100
PRE
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

IMpassion132化疗加或不加阿特珠单抗治疗早期复发性不可切除的局部晚期或转移性三阴性乳腺癌的双盲随机III期试验

2024-07-014
OAAI
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study (vol 15, 2691, 2024)
2024-05-100
OAAI
Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
2024-05-020
PRE
Anti-Mullerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials
2024-05-020
PRE
NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2-Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET)
2024-05-020
PRE
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+early-breast cancer (EBC)
2024-05-020
PRE
INAVO122: a Phase III study of maintenance inavolisib or placebo plus pertuzumab plus trastuzumab following induction with pertuzumab plus trastuzumab plus a taxane in patients with PIK3CAmutated, HER2-positive advanced breast cancer
2024-05-020
PRE
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
2024-03-274
OAAI